1-4 of 4
Grant E. Blouse
Close
Sort by
Journal Articles

Subcutaneous Marzeptacog Alfa (Activated) Versus Intravenous rFVIIa for Treatment of Episodic Bleeding in FVIII Deficient Hemophilia a Rats

Tom Knudsen, Peter Johansen, Jill Reckless, Shraddha Desai, Grant E. Blouse
Journal: Blood
Blood (2021) 138 (Supplement 1): 3181.
https://doi.org/10.1182/blood-2021-151284
Published: 2021
Journal Articles

Gene therapy for hemophilia B using CB 2679d-GT: a novel factor IX variant with higher potency than factor IX Padua

Brief Report
Nisha Nair, Dries De Wolf, Phuong Anh Nguyen, Quang Hong Pham, Ermira Samara-Kuko, Jeff Landau, Grant E. Blouse, Marinee K. Chuah, Thierry VandenDriessche
Journal: Blood
Blood (2021) 137 (21): 2902–2906.
https://doi.org/10.1182/blood.2020006005
Published: 2021
Includes: Supplemental data
Journal Articles

Fast Onset of Action of Subcutaneously Administered Marzeptacog Alfa (Activated) Supports on-Demand Treatment in Hemophilia a Mice

Frank Del Greco, MBA, Linda Neuman, MD, Howard Levy, PhD MBBChir, Jill Reckless, Tom Knudsen, PhD DVM, Grant E. Blouse, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2420.
https://doi.org/10.1182/blood-2019-128971
Published: 2019
Journal Articles

The Combination of Marzeptacog Alfa (Activated) or Eptacog Alfa (Activated) with Emicizumab Appears Comparable As Assessed By the Thrombin Generation Test in Hemophilia a Plasma

Tom Knudsen, PhD DVM, Brajesh Kumar, Frank Del Greco, MBA, Linda Neuman, MD, Howard Levy, PhD MBBChir, Grant E. Blouse, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1112.
https://doi.org/10.1182/blood-2019-130559
Published: 2019